- HIV and hepatitis testing includes a range of diagnostic tools used to detect the presence of HIV and various hepatitis viruses (A, B, C, D, E), playing a crucial role in early detection, treatment planning, and disease surveillance
- The market is significantly driven by the growing global burden of these infections, increasing awareness and screening initiatives, and the need for timely diagnosis to prevent disease progression and transmission. The demand is particularly high in low- and middle-income countries with high prevalence rates and limited access to healthcare
- North America dominates the market, owing to its well-established healthcare infrastructure, high testing penetration, and early adoption of advanced diagnostic technologies
- For instance, the U.S. Centers for Disease Control and Prevention (CDC) supports extensive HIV and hepatitis testing programs, while private and public health sectors consistently invest in innovative testing solutions
- Globally, HIV and hepatitis diagnostic tests are among the most widely adopted infectious disease tests, second only to tuberculosis diagnostics, underscoring their essential role in global health strategies and clinical decision-making
